<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1060">
  <stage>Registered</stage>
  <submitdate>7/02/2006</submitdate>
  <approvaldate>7/02/2006</approvaldate>
  <nctid>NCT00289484</nctid>
  <trial_identification>
    <studytitle>A Study of Omega-3 as an Augmentor of Antidepressant Treatment for Major Depression</studytitle>
    <scientifictitle>A Randomised, Double-Blind, Placebo Controlled Trial of Omega-3 Polyunsaturated Fatty Acid as an Augmentor of Antidepressant Medication for Major Depression.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>05156</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Major Depression</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Omega-3 Polyunsaturated Fatty Acids

Treatment: drugs: Omega-3 Polyunsaturated Fatty Acids


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change form pretreatment score on Depression Rating scale at 4 weeks</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Daily mood rating</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Weekly measure of depression</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Weekly measure of anxiety</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Weekly measure of functional status</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Participants must present with a first or new episode of DSM IV non-psychotic major
             depression warranting treatment with antidepressant mediation.

          -  Must be able to give informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of psychosis or mania/hypomania or personality disorder.

          -  Non-English speaking or otherwise unable to provide historical information.

          -  Having taken Omega-3 dietary supplements in the last 3 months.

          -  History of allergy to Omega-3 supplements, finfish or shellfish.

          -  Pregnancy, breast feeding or plans to become pregnant during course of study.

          -  Post-natal depression

          -  Current drug or alcohol abuse or dependence or history of abuse or dependence over the
             last 12 months.

          -  Unstable thyroid function

          -  Hepatic or renal impairment or other medical conditions that may interfere with the
             absorption and metabolism of Omega-3 polyunsaturated fatty acids

          -  Coagulopathy or anticoagulant treatment due to theoretical bleeding risk.

          -  Patients who, in the investigator's judgment pose a current serious suicidal or other
             safety risk, or patients who will not likely be able to comply with the study
             protocol.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>The University of New South Wales/Black Dog Institute - Sydney</hospital>
    <postcode>2031 - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The University of New South Wales</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Your Health Inc.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Sphere Healthcare</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Ocean Nutrition</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether augmentation of antidepressant medication
      with Omega-3 polyunsaturated fatty acids increases the speed and degree of improvement for
      patients with major depression</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00289484</trialwebsite>
    <publication>Rees AM, Austin MP, Parker G. Role of omega-3 fatty acids as a treatment for depression in the perinatal period. Aust N Z J Psychiatry. 2005 Apr;39(4):274-80. Review.
Parker, G., Gibson, N., Brotchie, H., Heruc, G., Rees, A-M., Hadzi-Pavlovic, D. Omega-3 Fatty Acids and Mood Disorders. American Journal of Psychiatry (In Press, 2006).
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gordon B Parker, Dsc MD PhD</name>
      <address>Professor, School of Psychiatry UNSW and Exectutive Director, Black Dog Institute</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Catherine Owen, Bsc (hons)</name>
      <address />
      <phone>(02) 9382 3717</phone>
      <fax />
      <email>cath.owen@unsw.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>